Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer

www.cancertherapyadvisor.com

People with PD-L1– favorable growths appointed to atezolizumab plus nab-paclitaxel had a 2-month rise in PFS contrasted with sugar pill plus nab-paclitaxel (7.5 vs 5.0 months; Human Resources=0.62; P

Ryan
Ryan

No Comments

Write a Reply or Comment